Literature DB >> 12601767

Antibody response after RSV infection in children younger than 1 year of age living in a rural area of Mozambique.

Anna Roca1, Llorenç Quintó, Fátima Abacassamo, Maria Paz Loscertales, Francesc Xavier Gómez-Olivé, Fiona Fenwick, Patricia A Cane, Juan Carlos Saiz, Geoffrey Toms, Pedro L Alonso.   

Abstract

Serological responses have been studied in respiratory syncytial virus (RSV) infected children < 1 year of age attending the outpatient department of the Manhiça District Hospital (Mozambique). Molecular characterization of viral RNA in nasopharyngeal aspirates from the infected children indicated a high level of genetic uniformity among the infecting viruses, all of which belonged to a single genotype of RSV group A. A representative virus strain, Moz00, was isolated from one of the infants and was used, together with the group A strain A2 and the group B strain 8/60, as antigens in the quantification of infant antibody responses. In this study, 97.5% (39/40) and 96.4% (27/28) of infected children produced an antibody response against Moz00 detected by the membrane fluorescent antibody test (MFAT) and the neutralization test (NT), respectively. Seroconversion rates decreased when the A2 and 8/60 strains were used as antigen in MFAT (95.4% and 88.2%, respectively) or NT (81.8% and 54.5%, respectively), indicating that antibody responses had both group- and strain-specific components. Antibodies in convalescent sera of infected children were compared with maternally derived antibodies detected in a group of children also < 1 year of age, but with no evidence of RSV infection. The convalescent sera exhibited reduced neutralizing capacity when the 8/60 strain was used as antigen (P = 0.028), suggesting that the infant antibody response lacks neutralizing capacity against strains of the heterologous virus group. Restricted cross-reactivity and neutralizing capacity of antibodies generated by young children might be expected to induce only moderate protection in subsequent epidemics against genetically distant strains. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601767     DOI: 10.1002/jmv.10348

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Antibody response to respiratory syncytial virus infection in children <18 months old.

Authors:  Susanna Esposito; Elisa Scarselli; Mara Lelii; Alessia Scala; Alessandra Vitelli; Stefania Capone; Marco Fornili; Elia Biganzoli; Annalisa Orenti; Alfredo Nicosia; Riccardo Cortese; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

2.  The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations.

Authors:  John V Williams; Jörn-Hendrik Weitkamp; David L Blum; Bonnie J LaFleur; James E Crowe
Journal:  Mol Immunol       Date:  2009-10-04       Impact factor: 4.407

3.  Performance evaluation of antibody tests for detecting infant respiratory syncytial virus infection.

Authors:  Samadhan J Jadhao; Binh Ha; Courtney McCracken; Tebeb Gebretsadik; Christian Rosas-Salazar; James Chappell; Suman Das; Tina Hartert; Larry J Anderson
Journal:  J Med Virol       Date:  2020-12-29       Impact factor: 20.693

4.  The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.

Authors:  Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

5.  A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life.

Authors:  Marie-Louise von Linstow; Mette Høgh; Svein Arne Nordbø; Jesper Eugen-Olsen; Anders Koch; Birthe Høgh
Journal:  Eur J Pediatr       Date:  2008-01-03       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.